Examkin

Question

Difficulty: MediumGastroenterology and Hepatology

A 45-year-old man presents to the gastroenterology clinic for chronic, watery diarrhea and recurrent abdominal pain. Over the past year, he has been treated for peptic ulcer disease with a high-dose proton pump inhibitor, but his symptoms have persisted and worsened. Upper gastrointestinal endoscopy reveals thickened gastric folds and multiple ulcerations in the stomach, distal duodenum, and proximal jejunum. A diagnosis of Zollinger-Ellison syndrome (gastrinoma) is suspected. Arrange the following steps in the most appropriate diagnostic and therapeutic sequence for this patient.

  1. 1Discontinue the proton pump inhibitor and measure fasting serum gastrin concentration
  2. 2Perform a secretin stimulation test
  3. 3Perform somatostatin receptor scintigraphy (e.g., Ga-68 DOTATATE PET/CT)
  4. 4Proceed with surgical exploration and tumor resection

Answer

The correct sequence is: 1) Discontinue the proton pump inhibitor and measure fasting serum gastrin concentration, 2) Perform a secretin stimulation test, 3) Perform somatostatin receptor scintigraphy, 4) Proceed with surgical exploration and tumor resection.
The evaluation of suspected Zollinger-Ellison syndrome must follow a strict, sequential approach. First, biochemical evidence of inappropriate hypergastrinemia must be established. Because proton pump inhibitors artificially elevate gastrin levels by removing the negative feedback of gastric acid, they must be discontinued prior to measuring fasting serum gastrin. Second, if the fasting gastrin level is elevated but not definitively diagnostic (>1,000 pg/mL is diagnostic, but 110-1,000 pg/mL requires confirmation), a secretin stimulation test is required; a paradoxical rise in gastrin confirms the presence of a gastrinoma. Third, once the biochemical diagnosis is secure, localization of the gastrinoma is performed. Somatostatin receptor scintigraphy (e.g., Ga-68 DOTATATE PET/CT) is the imaging modality of choice due to its high sensitivity for neuroendocrine tumors. Finally, if the tumor is localized and there is no evidence of unresectable metastasis (and no diffuse disease associated with MEN1), surgical exploration and resection are indicated for a potential cure.

Step-by-Step Solution

1
Identify the clinical presentation suggestive of a gastrinoma.
The patient has refractory peptic ulcer disease, distal ulcers, thickened gastric folds, and diarrhea, highly suggestive of Zollinger-Ellison syndrome.
Recognizing the syndrome dictates the specific diagnostic pathway for neuroendocrine tumors.
2
Determine the initial biochemical test required.
The first step is measuring fasting serum gastrin off proton pump inhibitor therapy.
Proton pump inhibitors suppress acid production, leading to physiologic hypergastrinemia, which can cause false-positive results.
3
Identify the confirmatory biochemical test if initial levels are equivocal.
A secretin stimulation test is the next step.
Normal G cells are inhibited by secretin, but neoplastic gastrinoma cells are paradoxically stimulated, resulting in a dramatic rise in gastrin levels.
4
Determine the modality for tumor localization.
Somatostatin receptor scintigraphy (such as Ga-68 DOTATATE PET/CT) is performed.
Gastrinomas express high levels of somatostatin receptors, making this the most sensitive imaging modality for localizing the primary tumor and detecting metastases.
5
Select the definitive treatment.
Surgical exploration and resection.
For sporadic, localized gastrinomas, surgical resection offers the only chance for a definitive cure.

Key Concept

The step-wise diagnostic and management algorithm for Zollinger-Ellison syndrome (gastrinoma)
Estimated Time:1m 30s
Rate this question

Topics

Gastroenterology and Hepatology

More questions from this topic